Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation

• US 7,922,709 B2
• Filed: 11/30/2005
• Issued: 04/12/2011
• Est. Priority Date: 07/13/1998
• Status: Expired due to Term

• Current Assignee: Inovio Pharmaceuticals, Inc.
• Original Assignee: Genetronics, Inc. (Inovio Pharmaceuticals, Inc.)
• Inventors: Zhang, Lei, Rabussay, Dietmar P.
• Primary Examiner(s): Lucchesi; Nicholas D
• Assistant Examiner(s): Bouchelle; Laura A
• Application Number:
  US11/291,459
• Publication Number:
  US 20060084938A1
• Time in Patent Office: 1,959 Days
• Field of Search: 604 19- 21, 604/49, 604313-316, 604/501, 606/41, 606/42, 606/44, 606 48- 50, 607/115, 607/120
• US Class Current: 604/501
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation

Abstract

In vivo methods are provided for using an electric field to delivery therapeutic or immunizing treatment to a subject by applying non-invasive, user-friendly electrodes to the surface of the skin. Thus, therapeutic or immunizing agents can be delivered into cells of skin for local and systemic treatments or for immunization with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Claims

1. A method for delivering an isolated polynucleotide species that encodes a therapeutic gene product into skin cells of a subject, comprising:

a) introducing about 0.05 μ

g to about 100 μ

g of at least one isolated polynucleotide species encoding a therapeutic gene product into each of one or more skin tissue sites of a subject; and

b) substantially contemporaneously with the introduction of the isolated polynucleotide species, applying one or more electric pulses across at least two noninvasive electrodes to generate a total charge transfer of about one mC to about 1000 mC per skin tissue site so as to allow the polynucleotide species to enter cells within the skin tissue site, thereby delivering the isolated polynucleotide species into skin cells of the subject.

2. A method according to claim 1, wherein the total charge transfer at the skin tissue site(s) is (are) about 10 mC/cm² to about 20 mC/cm².

3. A method according to claim 2, wherein about 0.1 μ

g to about 10 μ

g of the isolated polynucleotide species is introduced per skin tissue site.

4. A method according to claim 1, further comprising reducing resistance of the stratum corneum in the skin tissue site prior to generating the charge transfer by a procedure selected from the group consisting of laser treatment, tape stripping, electroporation, ultrasound, penetration enhancing chemicals, and any combination thereof.

5. A method according to claim 4, wherein the isolated polynucleotide is applied topically to the skin tissue site.

6. A method according to claim 1, wherein the non-invasive electrodes are contained in a meander electrode or are caliper electrodes.

7. A method according to claim 6, wherein the non-invasive electrodes are contained in a meander electrode having electrode spacing of about 0.2 mm.

8. A method according to claim 6, wherein the non-invasive electrodes are caliper electrodes and the charge transfer is generated by applying the one or more electric pulses so as to cause a nominal field strength in the skin tissue site of about 200 V/cm to about 2500 V/cm.

9. A method according to claim 1, wherein the one or more electric pulses are applied at a voltage of about 40 V to about 100 V.

10. A method according to claim 9, wherein each electric pulse is applied for a period of about 1 ms to about 100 ms.

11. A method according to claim 1, wherein more than one electric pulse is applied, and wherein the frequency of application of the electric pulses is about 1 to about 10 Hz.

12. A method according to claim 1, wherein from one to about 30 of the electric pulses are applied.

13. A method according to claim 1, wherein the subject is a mammal.

14. A method according to claim 1, wherein the subject is a human.

15. A method according to claim 1, wherein the polynucleotide is selected from the group consisting of double-stranded DNA, single-stranded DNA, complexed DNA, formulated DNA, encapsulated DNA, naked RNA, encapsulated RNA, and combinations thereof.

16. A method according to claim 1, wherein the polynucleotide encoding the therapeutic gene product is contained in a DNA vector.

17. A method according to claim 16, wherein the polynucleotide encoding the therapeutic gene product is operably associated with a regulatory sequence for expression of the therapeutic polypeptide in cells.

18. A method according to claim 17, wherein the regulatory sequence comprises a promoter.

19. A method according to claim 18, wherein the promoter is skin cell specific.

20. A method according to claim 18, wherein the therapeutic gene product is selected from the group consisting of a peptide and a polypeptide.